Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BZDS1901 in MSLN-positive Advanced Solid Tumors
NCT05089266Phase 1Unknown
- Sponsor
- Shanghai Cell Therapy Group
- Start
- Nov 2021
- Primary completion
- Jul 2024
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of M28z1XXPD1DNR in solid tumor, ovarian cancer, cholangiocarcinoma (CCA) and 1 more, sponsored by Shanghai Cell Therapy Group. Primary endpoint: Dose-limiting toxicity at 12 months. Status: unknown.
02
Drugs
M28z1XXPD1DNR
03
Conditions
solid tumorovarian cancercholangiocarcinoma (CCA)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05089266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05089266.